New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury
Mucositis is a common complication of chemotherapy, radiotherapy and targeted agents. It often affects compliance to anticancer therapies as it frequently causes schedule delays, interruptions or discontinuations of treatment. Moreover, the economic impact related to the management of mucositis is t...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2017-06-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/article/10.3389/fphar.2017.00354/full |
| _version_ | 1818959361589903360 |
|---|---|
| author | Marika Cinausero Giuseppe Aprile Giuseppe Aprile Paola Ermacora Debora Basile Maria G. Vitale Valentina Fanotto Giuseppe Parisi Lorenzo Calvetti Stephen T. Sonis Stephen T. Sonis Stephen T. Sonis |
| author_facet | Marika Cinausero Giuseppe Aprile Giuseppe Aprile Paola Ermacora Debora Basile Maria G. Vitale Valentina Fanotto Giuseppe Parisi Lorenzo Calvetti Stephen T. Sonis Stephen T. Sonis Stephen T. Sonis |
| author_sort | Marika Cinausero |
| collection | DOAJ |
| description | Mucositis is a common complication of chemotherapy, radiotherapy and targeted agents. It often affects compliance to anticancer therapies as it frequently causes schedule delays, interruptions or discontinuations of treatment. Moreover, the economic impact related to the management of mucositis is topical and several estimations of additional hospital costs due to this clinical condition have been recently reported. The ability to determine risk factors for mucositis, to early detect its onset, to assess correctly the degree of this toxicity and to plan its multidisciplinary management are all key elements to guarantee the quality of life of patients and to avoid useless dose reduction or interruption of treatment. The pathogenesis of mucositis is multifactorial and it is classily subdivided into oral and gastrointestinal mucositis according to its anatomic presentation. Treatment and patients’ related factors might help in predicting the frequency and the potential degree of symptoms onset. Here we discuss about clinical presentation and pathogenesis of mucositis in relation to different kinds of treatments. Moreover, we focus on therapeutic and prevention strategies, describing past and present management according to international guidelines and the most promising new data about agents potentially able to further improve the treatment of mucositis in the next future. |
| first_indexed | 2024-12-20T11:40:25Z |
| format | Article |
| id | doaj.art-f16902658b3b431da5d4c9c4ff6b1e2d |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-20T11:40:25Z |
| publishDate | 2017-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-f16902658b3b431da5d4c9c4ff6b1e2d2022-12-21T19:42:01ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122017-06-01810.3389/fphar.2017.00354260218New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal InjuryMarika Cinausero0Giuseppe Aprile1Giuseppe Aprile2Paola Ermacora3Debora Basile4Maria G. Vitale5Valentina Fanotto6Giuseppe Parisi7Lorenzo Calvetti8Stephen T. Sonis9Stephen T. Sonis10Stephen T. Sonis11Department of Oncology, University and General HospitalUdine, ItalyDepartment of Oncology, University and General HospitalUdine, ItalyDepartment of Oncology, San Bortolo General HospitalVicenza, ItalyDepartment of Oncology, University and General HospitalUdine, ItalyDepartment of Oncology, University and General HospitalUdine, ItalyDepartment of Oncology, University and General HospitalUdine, ItalyDepartment of Oncology, University and General HospitalUdine, ItalyDepartment of Oncology, University and General HospitalUdine, ItalyDepartment of Oncology, San Bortolo General HospitalVicenza, ItalyDivisions of Oral Medicine, Brigham and Women’s Hospital, BostonMA, United StatesDana-Farber Cancer InstituteBoston, MA, United StatesBiomodels LLC, WatertownMA, United StatesMucositis is a common complication of chemotherapy, radiotherapy and targeted agents. It often affects compliance to anticancer therapies as it frequently causes schedule delays, interruptions or discontinuations of treatment. Moreover, the economic impact related to the management of mucositis is topical and several estimations of additional hospital costs due to this clinical condition have been recently reported. The ability to determine risk factors for mucositis, to early detect its onset, to assess correctly the degree of this toxicity and to plan its multidisciplinary management are all key elements to guarantee the quality of life of patients and to avoid useless dose reduction or interruption of treatment. The pathogenesis of mucositis is multifactorial and it is classily subdivided into oral and gastrointestinal mucositis according to its anatomic presentation. Treatment and patients’ related factors might help in predicting the frequency and the potential degree of symptoms onset. Here we discuss about clinical presentation and pathogenesis of mucositis in relation to different kinds of treatments. Moreover, we focus on therapeutic and prevention strategies, describing past and present management according to international guidelines and the most promising new data about agents potentially able to further improve the treatment of mucositis in the next future.http://journal.frontiersin.org/article/10.3389/fphar.2017.00354/fullgastrointestinal mucositisoral mucositispathobiologyanticancer treatmentmanagement |
| spellingShingle | Marika Cinausero Giuseppe Aprile Giuseppe Aprile Paola Ermacora Debora Basile Maria G. Vitale Valentina Fanotto Giuseppe Parisi Lorenzo Calvetti Stephen T. Sonis Stephen T. Sonis Stephen T. Sonis New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury Frontiers in Pharmacology gastrointestinal mucositis oral mucositis pathobiology anticancer treatment management |
| title | New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury |
| title_full | New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury |
| title_fullStr | New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury |
| title_full_unstemmed | New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury |
| title_short | New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury |
| title_sort | new frontiers in the pathobiology and treatment of cancer regimen related mucosal injury |
| topic | gastrointestinal mucositis oral mucositis pathobiology anticancer treatment management |
| url | http://journal.frontiersin.org/article/10.3389/fphar.2017.00354/full |
| work_keys_str_mv | AT marikacinausero newfrontiersinthepathobiologyandtreatmentofcancerregimenrelatedmucosalinjury AT giuseppeaprile newfrontiersinthepathobiologyandtreatmentofcancerregimenrelatedmucosalinjury AT giuseppeaprile newfrontiersinthepathobiologyandtreatmentofcancerregimenrelatedmucosalinjury AT paolaermacora newfrontiersinthepathobiologyandtreatmentofcancerregimenrelatedmucosalinjury AT deborabasile newfrontiersinthepathobiologyandtreatmentofcancerregimenrelatedmucosalinjury AT mariagvitale newfrontiersinthepathobiologyandtreatmentofcancerregimenrelatedmucosalinjury AT valentinafanotto newfrontiersinthepathobiologyandtreatmentofcancerregimenrelatedmucosalinjury AT giuseppeparisi newfrontiersinthepathobiologyandtreatmentofcancerregimenrelatedmucosalinjury AT lorenzocalvetti newfrontiersinthepathobiologyandtreatmentofcancerregimenrelatedmucosalinjury AT stephentsonis newfrontiersinthepathobiologyandtreatmentofcancerregimenrelatedmucosalinjury AT stephentsonis newfrontiersinthepathobiologyandtreatmentofcancerregimenrelatedmucosalinjury AT stephentsonis newfrontiersinthepathobiologyandtreatmentofcancerregimenrelatedmucosalinjury |